Senate Approves Additional FDA Funding
The US Senate approved a measure (HR 2642) that would provide the US Food and Drug Administration with $275 million in additional funding under a supplemental appropriations bill. The measure now goes before the House.
Washington, DC (May 22)-The US Senate approved a measure (HR 2642) that would provide the US Food and Drug Administration with $275 million in additional funding under a supplemental appropriations bill. The measure now goes before the House.
Earlier this month, FDA Commissioner Andrew von Eschenbach outlined in a letter to Arlen Specter, ranking member of the Senate Subcommittee on Labor, Health and Human Services, Education and Regulated Agencies, the agency's immediate needs as part of discussions for a supplemental budget request. The $275-million request included $100 million for drug, medical device, and biologics safety, $125 million for food protection, and $50 million for modernizing FDA’s science and workforce.
FDA’s request for an additional $100 million in drug-safety funding would allow for 120 more foreign inspections and 575 more domestic inspections. It would also support additional measures for risk-based inspection and compliance. These measures include improvements to laboratory infrastructure for rapid analysis of product and ingredient content, increasing import exams and sample/laboratory analysis, improvements in IT infrastructure, and allowing FDA to expand globally.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
